A multicenter evaluation of the HeartMate 3 risk score
Copyright © 2023 International Society for the Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved..
BACKGROUND: The Heartmate 3 (HM3) risk score (HM3RS) was derived and validated internally from within the Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3 (MOMENTUM 3) trial population and provides 1- and 2-year mortality risk prediction for patients in those before HM3 left ventricular assist device (LVAD) implantation. We aimed to evaluate the HM3RS in nontrial unselected patients, including those not meeting inclusion criteria for MOMENTUM 3 trial enrollment.
METHODS: Patients who underwent HM3 LVAD implant at 1 of 7 US centers between 2017 and 2021, with at least 1-year follow-up, were included in this analysis. Patients were retrospectively assessed for their eligibility for the MOMENTUM 3 trial based on study inclusion and exclusion criteria. HM3RS risk discrimination was evaluated using time-dependent receiver operating characteristic curve analysis for 1-year mortality for all patients and further stratified by MOMENTUM 3 trial eligibility. Kaplan-Meier curves were constructed using the HM3RS-based risk categories.
RESULTS: Of 521 patients included in the analysis, 266 (51.1%) would have met enrollment criteria for MOMENTUM 3. The 1- and 2-year survival for the total cohort was 85% and 81%, respectively. There was no statistically significant difference in survival between those who met and did not meet enrollment criteria at 1 (87% vs 83%; p = 0.21) and 2 years postimplant (80% vs 78%; p = 0.39). For the total cohort, HM3RS predicted 1-year survival with an area under the curve (AUC) of 0.63 (95% confidence interval [CI]: 0.57-0.69, p < 0.001). HM3RS performed better in the subset of patients meeting enrollment criteria: AUC 0.69 (95% CI:0.61-0.77, p < 0.001) compared to the subset that did not: AUC 0.58 (95% CI: 0.49-0.66, p = 0.078).
CONCLUSIONS: In this real-world evidence, multicenter cohort, 1- and 2-year survival after commercial HM3 LVAD implant was excellent, regardless of trial eligibility. The HM3RS provided adequate risk discrimination in "trial-like" patients, but predictive value was reduced in patients who did not meet trial criteria.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:43 |
|---|---|
| Enthalten in: |
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation - 43(2024), 4 vom: 01. März, Seite 626-632 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Grewal, Jagpreet [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Durable LVAD |
|---|
| Anmerkungen: |
Date Completed 18.03.2024 Date Revised 18.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.healun.2023.11.018 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365523585 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365523585 | ||
| 003 | DE-627 | ||
| 005 | 20240318233858.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.healun.2023.11.018 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1334.xml |
| 035 | |a (DE-627)NLM365523585 | ||
| 035 | |a (NLM)38061468 | ||
| 035 | |a (PII)S1053-2498(23)02156-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Grewal, Jagpreet |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A multicenter evaluation of the HeartMate 3 risk score |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.03.2024 | ||
| 500 | |a Date Revised 18.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 International Society for the Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: The Heartmate 3 (HM3) risk score (HM3RS) was derived and validated internally from within the Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3 (MOMENTUM 3) trial population and provides 1- and 2-year mortality risk prediction for patients in those before HM3 left ventricular assist device (LVAD) implantation. We aimed to evaluate the HM3RS in nontrial unselected patients, including those not meeting inclusion criteria for MOMENTUM 3 trial enrollment | ||
| 520 | |a METHODS: Patients who underwent HM3 LVAD implant at 1 of 7 US centers between 2017 and 2021, with at least 1-year follow-up, were included in this analysis. Patients were retrospectively assessed for their eligibility for the MOMENTUM 3 trial based on study inclusion and exclusion criteria. HM3RS risk discrimination was evaluated using time-dependent receiver operating characteristic curve analysis for 1-year mortality for all patients and further stratified by MOMENTUM 3 trial eligibility. Kaplan-Meier curves were constructed using the HM3RS-based risk categories | ||
| 520 | |a RESULTS: Of 521 patients included in the analysis, 266 (51.1%) would have met enrollment criteria for MOMENTUM 3. The 1- and 2-year survival for the total cohort was 85% and 81%, respectively. There was no statistically significant difference in survival between those who met and did not meet enrollment criteria at 1 (87% vs 83%; p = 0.21) and 2 years postimplant (80% vs 78%; p = 0.39). For the total cohort, HM3RS predicted 1-year survival with an area under the curve (AUC) of 0.63 (95% confidence interval [CI]: 0.57-0.69, p < 0.001). HM3RS performed better in the subset of patients meeting enrollment criteria: AUC 0.69 (95% CI:0.61-0.77, p < 0.001) compared to the subset that did not: AUC 0.58 (95% CI: 0.49-0.66, p = 0.078) | ||
| 520 | |a CONCLUSIONS: In this real-world evidence, multicenter cohort, 1- and 2-year survival after commercial HM3 LVAD implant was excellent, regardless of trial eligibility. The HM3RS provided adequate risk discrimination in "trial-like" patients, but predictive value was reduced in patients who did not meet trial criteria | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a HeartMate 3 | |
| 650 | 4 | |a durable LVAD | |
| 650 | 4 | |a mechanical circulatory support | |
| 650 | 4 | |a outcomes | |
| 650 | 4 | |a risk score | |
| 700 | 1 | |a Tripathi, Neeta |e verfasserin |4 aut | |
| 700 | 1 | |a Bortner, Ben |e verfasserin |4 aut | |
| 700 | 1 | |a Gregoski, Mathew J |e verfasserin |4 aut | |
| 700 | 1 | |a Cook, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Britt, Annie |e verfasserin |4 aut | |
| 700 | 1 | |a Hajj, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Rofael, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Sheidu, Mariyam |e verfasserin |4 aut | |
| 700 | 1 | |a Montovano, Margaret J |e verfasserin |4 aut | |
| 700 | 1 | |a Mehta, Mili |e verfasserin |4 aut | |
| 700 | 1 | |a Hajduczok, Alexander G |e verfasserin |4 aut | |
| 700 | 1 | |a Rajapreyar, Indranee N |e verfasserin |4 aut | |
| 700 | 1 | |a Brailovsky, Yevgeniy |e verfasserin |4 aut | |
| 700 | 1 | |a Genuardi, Michael V |e verfasserin |4 aut | |
| 700 | 1 | |a Kanwar, Manreet K |e verfasserin |4 aut | |
| 700 | 1 | |a Atluri, Pavan |e verfasserin |4 aut | |
| 700 | 1 | |a Lander, Matthew |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Palak |e verfasserin |4 aut | |
| 700 | 1 | |a Hsu, Steven |e verfasserin |4 aut | |
| 700 | 1 | |a Kilic, Arman |e verfasserin |4 aut | |
| 700 | 1 | |a Houston, Brian A |e verfasserin |4 aut | |
| 700 | 1 | |a Mehra, Mandeep R |e verfasserin |4 aut | |
| 700 | 1 | |a Sheikh, Farooq H |e verfasserin |4 aut | |
| 700 | 1 | |a Tedford, Ryan J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation |d 1993 |g 43(2024), 4 vom: 01. März, Seite 626-632 |w (DE-627)NLM012612367 |x 1557-3117 |7 nnns |
| 773 | 1 | 8 | |g volume:43 |g year:2024 |g number:4 |g day:01 |g month:03 |g pages:626-632 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.healun.2023.11.018 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 43 |j 2024 |e 4 |b 01 |c 03 |h 626-632 | ||